Entera Bio (ENTX) EBT Margin (2021 - 2025)

Entera Bio has disclosed EBT Margin across 4 years of filings, most recently posting 6102.38% for Q1 2025.

• Quarterly EBT Margin changed N/A year-over-year to 6102.38% in Q1 2025, while the trailing twelve-month figure through Dec 2025 was 27600.0% (down 2228122.0% YoY) and the FY2025 annual result came in at 27235.71%, down 2197218.0% from the prior year.
• EBT Margin slipped to 6102.38% in Q1 2025, from 2858.54% in the prior quarter.
• Over five years, EBT Margin peaked at 1471.34% in Q1 2021 and troughed at 35912.5% in Q3 2022.
• A 4-year average of 8283.82% and a median of 4717.32% in 2024 frame the typical range for EBT Margin.
• Biggest YoY gain for EBT Margin was 410366 bps in 2022; the steepest drop was 3360750 bps in 2022.
• Tracing ENTX's EBT Margin over 4 years: stood at 2493.94% in 2021, then plunged by 782 bps to 22007.14% in 2022, then surged by 87 bps to 2858.54% in 2024, then slumped by 113 bps to 6102.38% in 2025.
• Business Quant data shows ENTX's EBT Margin at 6102.38% in Q1 2025, 2858.54% in Q4 2024, and 7192.86% in Q3 2024.